#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0012] As has already been explained above, this method is technically complex because of the use of a centrifuge.
1-1	0-1	[	_	_	
1-2	1-5	0012	_	_	
1-3	5-6	]	_	_	
1-4	7-9	As	_	_	
1-5	10-13	has	_	_	
1-6	14-21	already	_	_	
1-7	22-26	been	_	_	
1-8	27-36	explained	_	_	
1-9	37-42	above	_	_	
1-10	42-43	,	_	_	
1-11	44-48	this	_	_	
1-12	49-55	method	_	_	
1-13	56-58	is	_	_	
1-14	59-70	technically	_	_	
1-15	71-78	complex	_	_	
1-16	79-86	because	_	_	
1-17	87-89	of	_	_	
1-18	90-93	the	_	_	
1-19	94-97	use	_	_	
1-20	98-100	of	_	_	
1-21	101-102	a	_	_	
1-22	103-113	centrifuge	_	_	
1-23	113-114	.	_	_	

#Text=Moreover, the plasma cannot be separated completely, because there may otherwise be a danger of mixing with erythrocytes.
#Text=[0013] U.S.
2-1	115-123	Moreover	_	_	
2-2	123-124	,	_	_	
2-3	125-128	the	_	_	
2-4	129-135	plasma	_	_	
2-5	136-142	cannot	_	_	
2-6	143-145	be	_	_	
2-7	146-155	separated	_	_	
2-8	156-166	completely	_	_	
2-9	166-167	,	_	_	
2-10	168-175	because	_	_	
2-11	176-181	there	_	_	
2-12	182-185	may	_	_	
2-13	186-195	otherwise	_	_	
2-14	196-198	be	_	_	
2-15	199-200	a	_	_	
2-16	201-207	danger	_	_	
2-17	208-210	of	_	_	
2-18	211-217	mixing	_	_	
2-19	218-222	with	_	_	
2-20	223-235	erythrocytes	_	_	
2-21	235-236	.	_	_	
2-22	237-238	[	*[1]	5-2[2_1]	
2-23	238-242	0013	*[1]	_	
2-24	242-243	]	*[1]	_	
2-25	244-247	U.S	*[1]	_	
2-26	247-248	.	*[1]	_	

#Text=Pat.
3-1	249-252	Pat	*[1]	_	
3-2	252-253	.	*[1]	_	

#Text=No. 5,527,472 likewise describes a closed system for separation of whole-blood constituents by means of centrifugation.
4-1	254-256	No	*[1]	_	
4-2	256-257	.	*[1]	_	
4-3	258-267	5,527,472	*[1]	_	
4-4	268-276	likewise	*[1]	_	
4-5	277-286	describes	*[1]	_	
4-6	287-288	a	*[1]	_	
4-7	289-295	closed	*[1]	_	
4-8	296-302	system	*[1]	_	
4-9	303-306	for	*[1]	_	
4-10	307-317	separation	*[1]	_	
4-11	318-320	of	*[1]	_	
4-12	321-332	whole-blood	*[1]	_	
4-13	333-345	constituents	*[1]	_	
4-14	346-348	by	*[1]	_	
4-15	349-354	means	*[1]	_	
4-16	355-357	of	*[1]	_	
4-17	358-372	centrifugation	*[1]	_	
4-18	372-373	.	*[1]	_	

#Text=In this method, the centrifugation initially takes place in a first bag with division into plasma and an erythrocyte concentrate, to which a substitute solution is then mixed.
5-1	374-376	In	_	_	
5-2	377-381	this	*[2]	_	
5-3	382-388	method	*[2]	_	
5-4	388-389	,	_	_	
5-5	390-393	the	_	_	
5-6	394-408	centrifugation	_	_	
5-7	409-418	initially	_	_	
5-8	419-424	takes	_	_	
5-9	425-430	place	_	_	
5-10	431-433	in	_	_	
5-11	434-435	a	_	_	
5-12	436-441	first	_	_	
5-13	442-445	bag	_	_	
5-14	446-450	with	_	_	
5-15	451-459	division	_	_	
5-16	460-464	into	_	_	
5-17	465-471	plasma	_	_	
5-18	472-475	and	_	_	
5-19	476-478	an	_	_	
5-20	479-490	erythrocyte	_	_	
5-21	491-502	concentrate	_	_	
5-22	502-503	,	_	_	
5-23	504-506	to	_	_	
5-24	507-512	which	_	_	
5-25	513-514	a	_	_	
5-26	515-525	substitute	_	_	
5-27	526-534	solution	_	_	
5-28	535-537	is	_	_	
5-29	538-542	then	_	_	
5-30	543-548	mixed	_	_	
5-31	548-549	.	_	_	

#Text=This mixture is then freed of leukocytes in a leukocyte-removing filter, so that an erythrocyte concentrate with substitute solution is obtained, but which still contains a high proportion of plasma.
#Text=[0014] This method too is technically complex, and a high proportion of blood plasma remains in the erythrocyte concentrate.
#Text=[0015] As a result of this, the object of the invention is to provide a technically simple method for separation of whole blood into an erythrocyte concentrate and a thrombocyte-containing plasma, in which as little plasma as possible remains in erythrocyte concentrate, and which method can be performed directly at the donor site, in particular without any delay after withdrawal.
6-1	550-554	This	*[3]	6-37[4_3]	
6-2	555-562	mixture	*[3]	_	
6-3	563-565	is	*[3]	_	
6-4	566-570	then	*[3]	_	
6-5	571-576	freed	*[3]	_	
6-6	577-579	of	*[3]	_	
6-7	580-590	leukocytes	*[3]	_	
6-8	591-593	in	*[3]	_	
6-9	594-595	a	*[3]	_	
6-10	596-614	leukocyte-removing	*[3]	_	
6-11	615-621	filter	*[3]	_	
6-12	621-622	,	*[3]	_	
6-13	623-625	so	*[3]	_	
6-14	626-630	that	*[3]	_	
6-15	631-633	an	*[3]	_	
6-16	634-645	erythrocyte	*[3]	_	
6-17	646-657	concentrate	*[3]	_	
6-18	658-662	with	*[3]	_	
6-19	663-673	substitute	*[3]	_	
6-20	674-682	solution	*[3]	_	
6-21	683-685	is	*[3]	_	
6-22	686-694	obtained	*[3]	_	
6-23	694-695	,	*[3]	_	
6-24	696-699	but	*[3]	_	
6-25	700-705	which	*[3]	_	
6-26	706-711	still	*[3]	_	
6-27	712-720	contains	*[3]	_	
6-28	721-722	a	*[3]	_	
6-29	723-727	high	*[3]	_	
6-30	728-738	proportion	*[3]	_	
6-31	739-741	of	*[3]	_	
6-32	742-748	plasma	*[3]	_	
6-33	748-749	.	*[3]	_	
6-34	750-751	[	_	_	
6-35	751-755	0014	_	_	
6-36	755-756	]	_	_	
6-37	757-761	This	*[4]	_	
6-38	762-768	method	*[4]	_	
6-39	769-772	too	_	_	
6-40	773-775	is	_	_	
6-41	776-787	technically	_	_	
6-42	788-795	complex	_	_	
6-43	795-796	,	_	_	
6-44	797-800	and	_	_	
6-45	801-802	a	_	_	
6-46	803-807	high	_	_	
6-47	808-818	proportion	_	_	
6-48	819-821	of	_	_	
6-49	822-827	blood	_	_	
6-50	828-834	plasma	_	_	
6-51	835-842	remains	_	_	
6-52	843-845	in	_	_	
6-53	846-849	the	_	_	
6-54	850-861	erythrocyte	_	_	
6-55	862-873	concentrate	_	_	
6-56	873-874	.	_	_	
6-57	875-876	[	_	_	
6-58	876-880	0015	_	_	
6-59	880-881	]	_	_	
6-60	882-884	As	_	_	
6-61	885-886	a	_	_	
6-62	887-893	result	_	_	
6-63	894-896	of	_	_	
6-64	897-901	this	_	_	
6-65	901-902	,	_	_	
6-66	903-906	the	_	_	
6-67	907-913	object	_	_	
6-68	914-916	of	_	_	
6-69	917-920	the	_	_	
6-70	921-930	invention	_	_	
6-71	931-933	is	_	_	
6-72	934-936	to	_	_	
6-73	937-944	provide	_	_	
6-74	945-946	a	_	_	
6-75	947-958	technically	_	_	
6-76	959-965	simple	_	_	
6-77	966-972	method	_	_	
6-78	973-976	for	_	_	
6-79	977-987	separation	_	_	
6-80	988-990	of	_	_	
6-81	991-996	whole	_	_	
6-82	997-1002	blood	_	_	
6-83	1003-1007	into	_	_	
6-84	1008-1010	an	_	_	
6-85	1011-1022	erythrocyte	_	_	
6-86	1023-1034	concentrate	_	_	
6-87	1035-1038	and	_	_	
6-88	1039-1040	a	_	_	
6-89	1041-1063	thrombocyte-containing	_	_	
6-90	1064-1070	plasma	_	_	
6-91	1070-1071	,	_	_	
6-92	1072-1074	in	_	_	
6-93	1075-1080	which	_	_	
6-94	1081-1083	as	_	_	
6-95	1084-1090	little	_	_	
6-96	1091-1097	plasma	_	_	
6-97	1098-1100	as	_	_	
6-98	1101-1109	possible	_	_	
6-99	1110-1117	remains	_	_	
6-100	1118-1120	in	_	_	
6-101	1121-1132	erythrocyte	_	_	
6-102	1133-1144	concentrate	_	_	
6-103	1144-1145	,	_	_	
6-104	1146-1149	and	_	_	
6-105	1150-1155	which	_	_	
6-106	1156-1162	method	_	_	
6-107	1163-1166	can	_	_	
6-108	1167-1169	be	_	_	
6-109	1170-1179	performed	_	_	
6-110	1180-1188	directly	_	_	
6-111	1189-1191	at	_	_	
6-112	1192-1195	the	_	_	
6-113	1196-1201	donor	_	_	
6-114	1202-1206	site	_	_	
6-115	1206-1207	,	_	_	
6-116	1208-1210	in	_	_	
6-117	1211-1221	particular	_	_	
6-118	1222-1229	without	_	_	
6-119	1230-1233	any	_	_	
6-120	1234-1239	delay	_	_	
6-121	1240-1245	after	_	_	
6-122	1246-1256	withdrawal	_	_	
6-123	1256-1257	.	_	_	

#Text=GENERAL DESCRIPTION OF THE INVENTION
7-1	1258-1265	GENERAL	_	_	
7-2	1266-1277	DESCRIPTION	_	_	
7-3	1278-1280	OF	_	_	
7-4	1281-1284	THE	_	_	
7-5	1285-1294	INVENTION	_	_	
